News

Video

Survey Explores Disparities Black Women With TNBC Face

Author(s):

A triple-negative breast cancer survivor discussed disparities she faced when undergoing cancer care.

Research has shown that Black women with triple-negative breast cancer (TNBC) tend to have higher mortality rates than their White counterparts. According to a survey conducted by the Tigerlily Foundation presented at the 2023 San Antonio Breast Cancer Symposium, more than half (52%) of Black women who participated reported that they did not receive biomarker-driven cancer care.

In an interview with CURE® TNBC survivor, Catrina Crutcher, discusses disparities that she faced during her cancer treatment.

“It's those type of disparities that I don't want Black women or brown women to experience because we all deserve the best treatment, no matter the insurance that we have,” she said.

Transcript

My experiences with disparities is I wasn't provided all of the necessary options for TNBC. It was straight, “only this medication, and this surgery and this chemotherapy and radiation therapy.” I was not provided the option of a clinical trial, or any type of other therapy besides immunotherapy, and for me, immunotherapy did not work, even though the FDA approved it. It gave me a pancreatitis. I was in the hospital for 10 days, I lost 34 pounds, and it was horrible. And I still have side effects from that experience. So I think, learning from my other peers who have been through breast cancer and who have triple-negative (breast cancer) learning that we don't have the same treatment options.

And also when it comes to insurance, I had shared a conversation with my doctor, (that) unfortunately, I lost my role, and my employer let me go. And I had told my oncologist, “Hey, I no longer have insurance.” And the fact that he immediately told me, “I cannot see you anymore,” was like, “Well, hold on. I have backups. I'm on my fiancé’s insurance.” But just to jump point and just say, “Oh, I can't see you again,” with that disparity without knowing what I have on the back burner or something just to have a backup plan. You didn't know that. For you to jump to that you can't see me and I’ve got to go to a lesser hospital that won't give me the treatment options. I didn't like that conversation. And I did have to correct him. And I did say something at that moment. It's those type of disparities that I don't want Black women or brown women to experience because we all deserve the best treatment, no matter the insurance that we have.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of doctor with brown hair.
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Related Content